Journal
ONCOGENE
Volume 36, Issue 45, Pages 6272-6281Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2017.225
Keywords
-
Funding
- Grants of the Cell Innovation Program
- P-Direct from the MEXT, Japan
- JSPS, Japan
- MHLW, Japan
- Program for Promotion of Fundamental Studies in Health Sciences
- NIBIO, Japan
- Takeda Science Foundation
- Mochida Memorial Research Foundation, Japan
- Yasuda Memorial Foundation
- Princess Takamatsu Cancer Research Fund
- Grants-in-Aid for Scientific Research [15K15581, 15K10610] Funding Source: KAKEN
Ask authors/readers for more resources
The androgen receptor (AR) has a central role in prostate cancer progression, particularly treatment-resistance disease including castration-resistant prostate cancer. Loss of the p53 tumor suppressor, a nuclear transcription factor, is also known to contribute to prostate malignancy. Here we report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of AR. G3BP2 induces both cell cycle progression and blocks apoptosis. Translocation of p53 is regulated by androgen-dependent sumoylation mediated by the G3BP2-interacting SUMO-E3 ligase, RanBP2. G3BP2 knockdown results in reduced tumor growth and increased nuclear p53 accumulation in mouse xenograft models of prostate cancer with or without long-term androgen deprivation. Moreover, strong cytoplasmic p53 localization is correlated clinically with elevated G3BP2 expression and predicts poor prognosis and disease progression to the hormone-refractory state. Our findings reveal a new AR-mediated mechanism of p53 inhibition that promotes treatment-resistant prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available